Astrana Health, Inc.
ASTH
$30.89
$0.070.23%
| Weiss Ratings | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.83 | |||
| Price History | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 5.81% | |||
| 30-Day Total Return | -13.67% | |||
| 60-Day Total Return | -7.71% | |||
| 90-Day Total Return | -34.22% | |||
| Year to Date Total Return | -4.07% | |||
| 1-Year Total Return | -22.13% | |||
| 2-Year Total Return | -21.16% | |||
| 3-Year Total Return | -37.86% | |||
| 5-Year Total Return | 181.59% | |||
| 52-Week High % Change | -51.12% | |||
| 52-Week Low % Change | 33.61% | |||
| Price | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $63.20 | |||
| 52-Week Low Price | $23.12 | |||
| 52-Week Low Price (Date) | Feb 28, 2025 | |||
| 52-Week High Price (Date) | Oct 16, 2024 | |||
| Valuation | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.55B | |||
| Enterprise Value | 1.53B | |||
| Price/Earnings (TTM) | 34.71 | |||
| Earnings Per Share (TTM) | 0.89 | |||
| Earnings Per Share Growth | -30.91% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.70 | |||
| Price/Book (Q) | 2.08 | |||
| Enterprise Value/Revenue (TTM) | 0.75 | |||
| Price | $30.89 | |||
| Enterprise Value/EBITDA (TTM) | 13.05 | |||
| Enterprise Value/EBIT | 17.13 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 46.34M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | 9.35% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 626 282 0288 | |||
| Address | 1668 S. Garfield Avenue Alhambra, CA 91801 | |||
| Website | www.astranahealth.com | |||
| Country | United States | |||
| Year Founded | 1994 | |||
| Profitability | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 4.39% | |||
| Profit Margin | 2.12% | |||
| Management Effectiveness | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.88% | |||
| Return on Equity | 10.80% | |||
| Income Statement | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 13.98M | |||
| Total Revenue (TTM) | 2.03B | |||
| Revenue Per Share | $43.90 | |||
| Gross Profit (TTM) | 271.39M | |||
| EBITDA (TTM) | 117.28M | |||
| EBIT (TTM) | 89.35M | |||
| Net Income (TTM) | 43.15M | |||
| Net Income Avl. to Common (TTM) | 43.15M | |||
| Total Revenue Growth (Q YOY) | 88.43% | |||
| Earnings Growth (Q YOY) | -8,173.40% | |||
| EPS Diluted (TTM) | 0.89 | |||
| EPS Diluted Growth (Q YOY) | -158.09% | |||
| Balance Sheet | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 290.85M | |||
| Cash Per Share (Q) | $6.28 | |||
| Total Current Assets (Q) | 638.50M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 514.17M | |||
| Current Ratio (Q) | 1.746 | |||
| Book Value Per Share (Q) | $14.87 | |||
| Total Assets (Q) | 1.35B | |||
| Total Current Liabilities (Q) | 365.61M | |||
| Total Debt (Q) | 471.84M | |||
| Total Liabilities (Q) | 840.73M | |||
| Total Common Equity (Q) | 712.72M | |||
| Cash Flow | ASTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -192.40M | |||
| Cash from Financing (TTM) | 135.15M | |||
| Net Change in Cash (TTM) | -5.05M | |||
| Levered Free Cash Flow (TTM) | 65.38M | |||
| Cash from Operations (TTM) | 52.20M | |||
